IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023

Rhea-AI Summary

IGM Biosciences (Nasdaq: IGMS) announced its fourth quarter and full year 2022 financial results will be reported on March 30, 2023. A live conference call and webcast will follow at 4:30 p.m. ET, where management will discuss financial outcomes and provide corporate updates. The company is focused on developing engineered IgM antibodies to address cancer, infectious diseases, and autoimmune conditions. IGM has a collaboration with Sanofi for IgM antibody development, enhancing its pipeline's potential. Investors can access the webcast via their website's 'Events and Presentations' section.

Positive

• Collaboration with Sanofi to develop IgM antibody therapies, potentially enhancing market position.
• Focus on a broad pipeline including treatments for cancer and autoimmune diseases.

Negative

• Awaiting financial results may indicate uncertainty in performance metrics.

MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 30, 2023.

In connection with the earnings release, IGM’s management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, March 30, 2023, to discuss the Company’s financial results and provide a corporate update. The webcast can be accessed by clicking the link: https://edge.media-server.com/mmc/p/ud83kix8 and will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website.

About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, infectious diseases and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.

Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

What date will IGM Biosciences report its fourth quarter 2022 financial results?

IGM Biosciences will report its fourth quarter financial results on March 30, 2023.

What is the time for the IGM Biosciences conference call?

The conference call will take place at 4:30 p.m. ET on March 30, 2023.

Where can I access the IGM Biosciences webcast for financial results?

The webcast can be accessed on the company’s website under the 'Events and Presentations' section.

What is the focus of IGM Biosciences as mentioned in the press release?

IGM Biosciences focuses on developing engineered IgM antibodies to treat cancer, infectious diseases, and autoimmune conditions.

Is there a collaboration mentioned in the IGM Biosciences press release?

Yes, IGM has a collaboration with Sanofi for the development of IgM antibody therapies.